BAX and cardiomyopathy: When dox was administered with a newly developed Bax allosteric inhibitor that modulate Bax function by conformational changes (BAI1 (Garner et al., 2019), Figure 2), cardiomyopathy was completely prevented without compromising the tumor-killing efficacy of dox treatment (Amgalan et al., 2020).